A trial of n−3 polyunsaturated fatty acids in the treatment of multiple sclerosis has been conducted over a 5-year period. 312 ambulant patients with acute remitting disease were randomly allocated to treatment and placebo controlled groups. Both were given dietary advice to increase the intake of n−6 polyunsaturated fatty acids and the treatment group in addition received capsules containing n−3 polyunsaturated fatty acids. The results showed no significant difference at the usual 95% confidence level, but there was a trend in favour of the n−3 treated group in all parameters examined including rate of deterioration, frequency and severity of attacks and number of patients improving or remaining unchanged during the course of the trial.
KeywordsInositol Phosphate Fatty Acid Supplementation Inuit Woman Erythrocyte Filtrability Glycerophosphate Acyltransferase
Unable to display preview. Download preview PDF.